Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | CMML: unmet needs and future outlooks

Eric Padron • 26 Aug 2022
Texas MPN Workshop 2022
Chronic Myelomonocytic Leukemia Leukemia Myeloproliferative Neoplasms Rare Diseases Azacitidine Decitabine

In this video, Eric Padron, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses unmet needs in chronic myelomonocytic leukemia (CMML), highlighting the need to develop therapies that modify disease and the importance of better understanding factors that lead to disease progression. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research Funding: Kura, Incyte, BMS
Honoraria: Blueprint, Novartis, Stem line, Taiho, Pharmaessentia

More from Eric Padron

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
1:31
The potential of bringing CAR-T therapy to MDS and challenges to overcome
Eric Padron • 9 Dec 2022
0:53
Challenges with bringing novel immune therapies to MDS
Eric Padron • 9 Dec 2022
1:32
Phase II efficacy and safety results of ruxolitinib for patients with symptomatic CMML
Eric Padron • 9 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals